Residency · Residency · Infectiousdisease

Clostridioides difficile Infection - Management and Prevention

Epidemiology and Pathogenesis

Burden of Disease

Clostridioides difficile infection represents one of the most significant healthcare-associated infections in the United States, with approximately 500,000 cases occurring annually and approximately 29,000 deaths within 30 days of diagnosis. While CDI was historically considered a predominantly healthcare-associated infection, community-associated CDI now accounts for 30 to 40 percent of cases, reflecting the broader reach of this pathogen. The recurrence rate escalates dramatically with each episode: 15 to 25 percent after the first episode, 40 to 60 percent after the second episode, and exceeding 60 percent after the third episode, illustrating the self-perpetuating nature of microbiome disruption. The NAP1/BI/027 hypervirulent strain has been associated with severe outbreaks and produces binary toxin (CDT) in addition to higher levels of toxins A and B, with characteristic fluoroquinolone resistance.

Pathogenesis

The pathogenesis of CDI follows a predictable sequence: disruption of normal colonic microbiota, most commonly by antibiotic exposure, permits colonization with C. difficile spores, which then germinate into vegetative cells capable of producing toxins. Toxin A (TcdA) is an enterotoxin that causes fluid secretion and mucosal inflammation. Toxin B (TcdB) is a cytotoxin approximately 1,000 times more potent than toxin A and serves as the primary virulence factor, glucosylating Rho GTPases, which disrupts the cytoskeleton and leads to cell death. Binary toxin (CDT), an ADP-ribosyltransferase produced by NAP1/027 and some other strains, has an independent but debated virulence role. The hallmark histopathologic finding is the pseudomembrane, consisting of volcano-like eruptions of fibrin, mucus, and inflammatory cells from damaged colonic mucosa.

Risk Factors

Antibiotic exposure is the single most important risk factor for CDI, with clindamycin, fluoroquinolones, cephalosporins, and carbapenems carrying the highest risk, though virtually any antibiotic can precipitate CDI. Additional risk factors include advanced age above 65 years, hospitalization and healthcare exposure, proton pump inhibitor use (though this association remains controversial with only a modest effect size), immunosuppression from chemotherapy or solid organ transplant, inflammatory bowel disease, and a prior CDI episode.

Diagnosis

Testing Algorithm (Two-Step or Multistep)

The IDSA/SHEA 2017 guidelines recommend a multistep diagnostic algorithm for CDI. The first step uses a highly sensitive test such as glutamate dehydrogenase EIA or nucleic acid amplification testing as a screening tool. The second step employs toxin EIA, which detects free toxin A and B in the stool and confirms active toxin production. NAAT alone, while achieving sensitivity of 95 to 99 percent, detects both active infection and colonization, and its low positive predictive value in low-prevalence settings may lead to overdiagnosis. Toxin EIA alone has lower sensitivity at 60 to 80 percent but high specificity and detects clinically relevant toxin production. The optimal approach combines NAAT with reflexive toxin EIA: a positive NAAT with a negative toxin result may represent colonization versus early disease and requires clinical correlation.

Critical diagnostic principles include never testing asymptomatic patients, never testing formed stools, never testing patients who are actively receiving laxatives, and never using PCR as a test of cure, as PCR remains positive for weeks after clinical resolution.

Clinical Classification (IDSA/SHEA 2021 Update)

The IDSA/SHEA 2021 classification stratifies CDI into three severity categories. Non-severe CDI is defined by a white blood cell count of 15,000 or below and creatinine below 1.5 milligrams per deciliter. Severe CDI is defined by a white blood cell count above 15,000 or creatinine of 1.5 or above, at 1.5 times the baseline. Fulminant CDI is characterized by hypotension, shock, ileus, or megacolon.

<image>A diagnostic testing algorithm for C. difficile infection showing a multistep approach. Start with "Patient with ≥3 unformed stools in 24 hours (no laxatives)." Step 1: "GDH EIA Screen" with branches: "Negative → CDI unlikely, no further testing" and "Positive → proceed to Step 2." Step 2: "Toxin A/B EIA" with branches: "Positive → CDI CONFIRMED, classify severity and treat" and "Negative → INDETERMINATE result." For indeterminate: "Reflexive NAAT (PCR)" with branches: "Positive → Possible CDI (toxigenic C. difficile present but free toxin not detected; clinical correlation needed)" and "Negative → CDI unlikely." Include a sidebar showing when NOT to test: "formed stools, asymptomatic patients, on laxatives, test of cure." Use a clear diagnostic flowchart format with green (negative/stop), red (positive/treat), and yellow (indeterminate/correlate clinically) color coding.</image>

Treatment

Initial Episode - Non-Severe

Fidaxomicin 200 milligrams orally twice daily for 10 days is now the IDSA/SHEA 2021 preferred first-line agent, displacing vancomycin from its prior position of primacy. Oral vancomycin 125 milligrams four times daily for 10 days remains an acceptable alternative. Metronidazole 500 milligrams orally three times daily for 10 days has been downgraded from first-line therapy in the 2021 guidelines and should only be used when both fidaxomicin and vancomycin are unavailable, as it is inferior to vancomycin for clinical cure. The preference for fidaxomicin over vancomycin is driven by the MODIFY I and II trials, which demonstrated equivalent initial cure rates of approximately 90 percent but significantly lower recurrence rates with fidaxomicin at 13 percent versus 27 percent for vancomycin.

Initial Episode - Severe

Both fidaxomicin 200 milligrams twice daily for 10 days and vancomycin 125 milligrams four times daily for 10 days are appropriate for severe CDI. Fidaxomicin has not been as extensively studied in fulminant disease, and vancomycin remains the more commonly used agent in this setting.

Fulminant CDI

Fulminant CDI requires an intensified regimen of vancomycin 500 milligrams orally or via nasogastric tube four times daily combined with metronidazole 500 milligrams intravenously every 8 hours. When ileus prevents colonic delivery of oral vancomycin, vancomycin retention enemas at 500 milligrams in 100 milliliters of normal saline every 6 hours via rectal tube should be administered. Surgical consultation is essential, with subtotal colectomy indicated for toxic megacolon, perforation, and refractory shock. Diverting loop ileostomy with colonic lavage using vancomycin has emerged as an alternative to colectomy in select patients, with the Neal 2011 study demonstrating lower mortality compared to colectomy. Tigecycline has been used anecdotally as adjunctive therapy in fulminant CDI with limited evidence. Intravenous immunoglobulin has no evidence of benefit and is not recommended.

First Recurrence

The approach to a first recurrence depends on the therapy used for the initial episode. When the initial episode was treated with vancomycin, the preferred options include fidaxomicin 200 milligrams twice daily for 10 days, fidaxomicin extended-pulsed regimen consisting of 200 milligrams twice daily for 5 days followed by 200 milligrams once daily every other day for 20 days as established by the EXTEND trial, which achieved a recurrence rate of only 4 percent versus 17 percent with standard fidaxomicin dosing, or a vancomycin tapered and pulsed regimen. When the initial episode was treated with metronidazole, a standard course of vancomycin or fidaxomicin is appropriate.

Second or Subsequent Recurrence

For patients with two or more recurrences, options include fidaxomicin (standard or extended-pulsed) if not previously used, vancomycin taper and pulse, and fecal microbiota transplant, which is recommended for patients with two or more recurrences despite appropriate antibiotic therapy. FDA-approved microbiome therapeutics have expanded the therapeutic armamentarium: fecal microbiota live-jslm (Rebyota), administered rectally as a single dose, was approved in 2022, and fecal microbiota spores live-brpk (Vowst), administered as oral capsules over three days, was approved in 2023. Both agents reduce recurrence by approximately 30 to 40 percent absolute risk reduction compared to placebo in clinical trials.

Bezlotoxumab

Bezlotoxumab is a monoclonal antibody directed against toxin B that is administered as a single intravenous infusion at 10 milligrams per kilogram during CDI antibiotic treatment. It reduces recurrence by approximately 38 percent relative risk reduction, as demonstrated in the MODIFY I and II trials, and is indicated for patients at high risk for recurrence including those aged 65 and above, immunocompromised patients, patients with severe CDI, and those with a prior CDI episode. Bezlotoxumab does not treat active CDI and must be administered alongside CDI-directed antibiotics.

<image>A comprehensive CDI treatment algorithm organized by severity and recurrence. Top row: "Initial Episode" with three columns for "Non-Severe," "Severe," and "Fulminant," each listing specific regimens. Below, "First Recurrence" with treatment options branching based on initial therapy used. Below that, "Second+ Recurrence" showing fidaxomicin extended-pulsed, vancomycin taper/pulse, FMT, and FDA-approved microbiome therapeutics (Rebyota, Vowst). Include a sidebar for "Bezlotoxumab" showing indications (high-risk for recurrence) and timing (given during antibiotic course). At the bottom, show "Adjunctive Measures" including antibiotic stewardship, discontinue offending antibiotics, avoid PPIs if possible, avoid anti-motility agents. Use a tiered pyramid format with increasing severity and recurrence moving downward, color-coded green (non-severe), yellow (severe), red (fulminant).</image>

Prevention and Infection Control

Antibiotic Stewardship

Antibiotic stewardship is the most impactful prevention strategy for CDI. Restricting high-risk antibiotics, particularly fluoroquinolones, clindamycin, and broad-spectrum cephalosporins, consistently reduces CDI incidence, with fluoroquinolone restriction programs achieving 30 to 60 percent reductions in multiple institutional studies.

Infection Control Measures

Contact precautions with gown and gloves for patient contact and preferably a private room are standard. Hand hygiene must be performed with soap and water, as alcohol-based hand sanitizers do not kill C. difficile spores. Environmental cleaning requires hypochlorite-based disinfectants at a 1:10 bleach dilution or EPA-registered sporicidal agents, given that C. difficile spores can survive on surfaces for months. Contact precautions are maintained for the duration of diarrhea plus institution-specific additional time. Adjunctive environmental measures include ultraviolet light decontamination, hydrogen peroxide vapor, and antimicrobial-coated surfaces.

Primary Prevention -- No Role for Prophylactic Vancomycin (Routine)

While observational data suggest that oral vancomycin prophylaxis at 125 milligrams daily during systemic antibiotic courses may reduce CDI risk in high-risk patients, the IDSA does not currently recommend routine prophylaxis due to potential for VRE selection. Probiotics for CDI prevention, including Saccharomyces boulardii and Lactobacillus, have mixed evidence, and the AGA 2020 guidelines offer a conditional recommendation for select hospitalized patients on antibiotics, while cautioning against their use in immunocompromised or critically ill patients given the risk of fungemia with S. boulardii.

Key Clinical Pearls

• Fidaxomicin is now the preferred first-line agent for CDI (not just recurrences) -- lower recurrence rates than vancomycin with equivalent initial cure
• Metronidazole has been removed from first-line CDI therapy (IDSA 2021) -- it is inferior to vancomycin and should only be used when vancomycin and fidaxomicin are unavailable
• Do NOT test for C. difficile in asymptomatic patients or use PCR as test of cure -- PCR remains positive for weeks after clinical resolution
• Alcohol-based hand sanitizer does NOT kill C. difficile spores -- soap and water hand washing is mandatory
• Fidaxomicin extended-pulsed regimen (EXTEND trial) has the lowest recurrence rate of any antibiotic regimen for recurrent CDI (~4%)
• FMT and FDA-approved microbiome therapeutics have transformed management of multiply recurrent CDI -- cure rates >85%
• Bezlotoxumab is an adjunct (not a treatment) -- it prevents recurrence when given during the CDI treatment antibiotic course

References

1. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the IDSA and SHEA: 2021 focused update on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
2. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection (MODIFY I/II). N Engl J Med. 2011;364(5):422-431.
3. Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection (EXTEND). Lancet Infect Dis. 2018;18(3):296-307.
4. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-317.
5. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220-229.

Read this lecture as Markdown